Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Gets Second Interchangeable Insulin Glargine In US

Further FDA Approval For Rezvoglar Biosimilar Adds Second Interchangeable Option

Executive Summary

Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.

You may also be interested in...



Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy

Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.

Lannett Eyes Insulins Opportunity And Advances Respiratory Assets

Lannett has offered the latest updates on its pipeline of respiratory complex generics and insulin biosimilars – including the potential for the firm to receive the first US biosimilar aspart approval.

Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'

Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel